Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07644195 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers
A Phase 1 study, sponsored by Trellis Bioscience.
- Not yet
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT07644195 is a Phase 1 study that has not yet begun recruiting, run by Trellis Bioscience. The registered enrollment target is 14 participants.
The verdict
NCT07644195, a Phase 1 study, has not yet begun recruiting, sponsored by Trellis Bioscience.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study in healthy volunteers will provide a basis for evaluation of inhaled TRL1068 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data.
Interventions
- DRUG TRL1068, a human monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-10 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07644195
The ClinicalTrials.gov registry entry for NCT07644195 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trellis Bioscience, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRL1068, a human monoclonal antibody is the first listed.
NCT07644195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07644195 about?
NCT07644195 is a clinical study titled "Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers". This study in healthy volunteers will provide a basis for evaluation of inhaled TRL1068 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data.
What is the current status of trial NCT07644195?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2026-10. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07644195?
The interventions under investigation include: TRL1068, a human monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT07644195?
This trial is sponsored by Trellis Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.